INT67451

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1997
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 3.42
Pain Relevance 1.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SLURP1) extracellular region (SLURP1) cell adhesion (SLURP1)
Anatomy Link Frequency
blood 2
monocytes 1
GMC 1
EPI 1
SLURP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
adenocard 229 99.76 Very High Very High Very High
agonist 284 99.24 Very High Very High Very High
Pain 7 98.88 Very High Very High Very High
antagonist 70 97.60 Very High Very High Very High
narcan 1 95.96 Very High Very High Very High
Opioid 9 95.92 Very High Very High Very High
Potency 96 93.88 High High
Morphine 5 92.84 High High
withdrawal 1 88.00 High High
mu opioid receptor 2 75.00 Quite High
Disease Link Frequency Relevance Heat
Infection 139 99.82 Very High Very High Very High
Pain 7 98.88 Very High Very High Very High
Sprains And Strains 73 98.28 Very High Very High Very High
Nociception 3 96.96 Very High Very High Very High
Bordatella Infection 1 96.52 Very High Very High Very High
Diabetic Retinopathy 3 95.24 Very High Very High Very High
Renal Disease 3 94.72 High High
Hypertension 7 92.56 High High
Disease 37 92.28 High High
Diabetes Mellitus 12 91.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The anti-DC-SIGN antibodies that blocked DV infection of IL-4 treated MDMØ to the greatest degree (DC28 and 120612) are known to cross react with DC-SIGNR.
Positive_regulation (treated) of MDM associated with infection
1) Confidence 0.49 Published 2008 Journal PLoS Pathogens Section Body Doc Link PMC2233670 Disease Relevance 0.54 Pain Relevance 0
Surface expression of both MR and DC-SIGN is upregulated on MDMØ by IL-4 treatment (Figure 6A and 6B), consistent with previous data for DC-SIGN on human monocytes [20] and for MR on primary mouse MØ [19,21].
Positive_regulation (upregulated) of MDM in monocytes
2) Confidence 0.49 Published 2008 Journal PLoS Pathogens Section Body Doc Link PMC2233670 Disease Relevance 0.43 Pain Relevance 0
In the Phase II studies, blood samples were taken at fixed intervals eight times (15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 8 h, and 12 h) post treatment in Ghanaian children and nine times (30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h) in Thai adults after administration of rectal ARS.
Positive_regulation (administration) of ARS in blood
3) Confidence 0.10 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664603 Disease Relevance 0 Pain Relevance 0
In the Phase II studies, blood samples were taken at fixed intervals eight times (15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 8 h, and 12 h) post treatment in Ghanaian children and nine times (30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h) in Thai adults after administration of rectal ARS.
Positive_regulation (rectal) of ARS in blood
4) Confidence 0.10 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664603 Disease Relevance 0 Pain Relevance 0
Adenosine receptors (ARs) are G protein-coupled receptors, consisting of A1, A2A, A2B and A3 subtypes, activated by the endogenous agonist adenosine and blocked by natural antagonists, such as caffeine and theophylline.
Positive_regulation (activated) of ARs associated with adenocard, antagonist and agonist
5) Confidence 0.05 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2625337 Disease Relevance 0 Pain Relevance 0.29
In particular, participation of A2B ARs in the analgaesic effects mediated by caffeine in an acute animal model of nociception (hot-plate test) has been documented [41].
Positive_regulation (participation) of ARs associated with nociception
6) Confidence 0.05 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.71 Pain Relevance 0.63
Identification of pharmacological agents able to specifically activate A2B ARs has been purported to be of therapeutic importance in protecting against glomerular remodeling associated with glomerulosclerosis, renal disease and abnormal GMC growth associated with hypertension and diabetes.
Positive_regulation (activate) of ARs in GMC associated with diabetes mellitus, hypertension and renal disease
7) Confidence 0.04 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 1.10 Pain Relevance 0.14
Of the examined molecules, the ones showing the capability to activate A2B ARs were inactive at the hA3 AR (Ki?
Positive_regulation (activate) of ARs
8) Confidence 0.04 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.12
Unlike EPI, which co-activates both ARs, NE, at the concentrations employed activates only ?
Positive_regulation (activates) of ARs in EPI
9) Confidence 0.03 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0 Pain Relevance 0.12
Investigation into the mechanism leading to up-regulation of AC revealed a 40% increase in the number of beta-2 ARs as assessed by [125I]-cyanopindolol binding experiments.
Positive_regulation (increase) of ARs
10) Confidence 0.03 Published 1997 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8996236 Disease Relevance 0.25 Pain Relevance 0.66
Results showed a 3.75±0.25 fold increase in sabA cDNA in H. pylori J99-arsS?
Positive_regulation (increase) of arsS
11) Confidence 0.01 Published 2008 Journal Microbiology Section Body Doc Link PMC2715451 Disease Relevance 0.40 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox